Sleep Control, GPCRs, and Glucose Metabolism
Hiroshi Tsuneki1, Toshiyasu Sasaoka1, Takeshi Sakurai2
1Department of Clinical Pharmacology, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.
Trends in Endocrinology and Metabolism: TEM
|July 28, 2016
Summary
Disrupted sleep impacts blood glucose and diabetes risk. Understanding how sleep medications affect glucose metabolism is vital for treating diabetic patients with sleep disorders.
Area of Science:
- Endocrinology and Sleep Medicine
Background:
- Modern lifestyles disrupt circadian rhythms, leading to sleep disturbances.
- Sleep disturbances are linked to dysregulated blood glucose and increased type 2 diabetes (T2D) risk.
- Current insomnia treatments target receptors like GABA, melatonin, and orexin.
Purpose of the Study:
- To review the beneficial impact of sleep on glucose metabolism.
- To explore the effects of anti-insomnia medications on glucose metabolism.
- To propose therapeutic strategies for sleep-related metabolic disorders.
Main Methods:
- Literature review of studies on sleep, circadian rhythms, and glucose metabolism.
- Analysis of mechanisms of action for common anti-insomnia drugs.
- Examination of the impact of these drugs on glucose regulation.
Main Results:
- Sleep plays a crucial role in maintaining normal glucose homeostasis.
- Anti-insomnia drugs may influence glucose metabolism through various receptor pathways.
- Specific drug effects on glucose require further investigation for diabetic populations.
Conclusions:
- Understanding sleep's role in glucose metabolism is key for managing T2D.
- Further research is needed on the metabolic effects of sleep medications in diabetic patients.
- Targeting sleep disturbances may offer a novel approach to managing metabolic disorders.
Related Concept Videos
01:02Glucose Homeostasis: Regulation of Blood Glucose
5.0K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
5.0K
01:16Hormones Regulating Blood Glucose
8.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
8.1K
01:09GPCRs Regulate Adenylyl Cylase Activity
8.1K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
8.1K
01:15Hypoglycemia and Glucagon
1.2K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.2K
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
3.0K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
3.0K
01:06Oral Hypoglycemic Agents: Glinides
837
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
837